Journal List > Diabetes Metab J > v.36(2) > 1084584

Diabetes Metab J. 2012 Apr;36(2):165-166. English.
Published online April 17, 2012.  https://doi.org/10.4093/dmj.2012.36.2.165
Copyright © 2012 Korean Diabetes Association
Response: Prevalence of Dyslipidemia among Korean Adults: Korea National Health and Nutrition Survey 1998-2005 (Diabetes Metab J 2012;36:43-55)
Hyeon Chang Kim
Department of Preventive Medicine, Yonsei University College of Medicine, Seoul, Korea.

Corresponding author: Hyeon Chang Kim. Department of Preventive Medicine, Yonsei University College of Medicine, 50 Yonsei-ro, Seodaemun-gu, Seoul 120-752, Korea. Email: hckim@yuhs.ac

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.



I deeply appreciate the comments of Dr. Bo Kyung Koo on our study "Prevalence of dyslipidemia among Korean adults: Korea National Health and Nutrition Survey 1998-2005" which was published in Diabetes & Metabolism Journal 2012;36:43-55. Metabolic syndrome is a cluster of multiple cardiometabolic risk factors, and prevalence of the syndrome is expected to increase in Korea [1, 2]. However, as Dr. Koo noted, common definitions of metabolic syndrome do not include elevated low density lipoprotein cholesterol (LDL-C) level, which is strongly associated with atherosclerotic cardiovascular disease [3, 4]. Dr. Koo also mentioned that evaluation of lipid abnormalities can provide additional predictive value compared to the presence of metabolic syndrome. This is an important comment and the reason why we reported prevalence of different forms of dyslipidemia including elevated total cholesterol, elevated triglycerides, elevated LDL-C, and reduced high density lipoprotein cholesterol (HDL-C).

Dr. Koo raised an epidemiologically and clinically relevant issue regarding the definition of low HDL-C level. In defining metabolic syndrome, the cutoff level of low HDL-C is frequently higher for women because women have a higher HDL-C distribution compared to men. According to the definition of metabolic syndrome in the NCEP-ATP III guidelines, reduced HDL-C level is defined as <50 mg/dL in women and <40 mg/dL in men [3]. However, the NCEP-ATP III criteria for reduced HDL-C might not be appropriate for the Korean population. Compared to the Western population, East Asian populations have lower HDL-C level and show smaller sex differences for this measure. Moreover, HDL-C levels among Koreans are even lower than those of other East Asian populations and show only a small sex difference [5-8]. In our study, the sex difference in mean HDL-C (women minus men) was only 2.1 mg/dL in 1998, 3.6 mg/dL in 2001, and 5.0 mg/dL in 2005 [9]. Because Korean women have relatively low HDL-C levels, 58.5% of women had an HDL-C level lower than 50 mg/dL in the 2001 KNHANES [10]. This caused the unusually high prevalence of metabolic syndrome, in comparison to the low prevalence of obesity, among Korean women in the literature. We also lack direct data regarding the level of HDL-C that should be treated. It is unclear whether women with HDL-C level of 40 to 49 mg/dL but without other lipid abnormalities should be treated. For these reasons, some Asian studies have used a cutoff for reduced HDL-C of <40 mg/dL for both sexes [6, 11].

Overall, I appreciate and agree with Dr. Koo's considerate comments. Great attention should be given to the working definitions when reporting and interpreting prevalence of metabolic syndrome and dyslipidemia. Further studies are also required to establish an appropriate definition of dyslipidemia in the Korean population.

Notes

No potential conflict of interest relevant to this article was reported.

References
1. Kahn R, Buse J, Ferrannini E, Stern M. American Diabetes Association; European Association for the Study of Diabetes. The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2005;28:2289–2304.
2. Park HS, Park CY, Oh SW, Yoo HJ. Prevalence of obesity and metabolic syndrome in Korean adults. Obes Rev 2008;9:104–107.
3. Expert Panel on Detection Evaluation and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001;285:2486–2497.
4. Alberti KG, Zimmet P, Shaw J. Metabolic syndrome: a new world-wide definition. A Consensus Statement from the International Diabetes Federation. Diabet Med 2006;23:469–480.
5. Hwang LC, Bai CH, Chen CJ. Prevalence of obesity and metabolic syndrome in Taiwan. J Formos Med Assoc 2006;105:626–635.
6. Gu D, Reynolds K, Wu X, Chen J, Duan X, Reynolds RF, Whelton PK, He J. InterASIA Collaborative Group. Prevalence of the metabolic syndrome and overweight among adults in China. Lancet 2005;365:1398–1405.
7. Arai H, Yamamoto A, Matsuzawa Y, Saito Y, Yamada N, Oikawa S, Mabuchi H, Teramoto T, Sasaki J, Nakaya N, Itakura H, Ishikawa Y, Ouchi Y, Horibe H, Shirahashi N, Kita T. Prevalence of metabolic syndrome in the general Japanese population in 2000. J Atheroscler Thromb 2006;13:202–208.
8. Kim HC, Kim DJ. Causes of different estimates of the prevalence of metabolic syndrome in Korea. Korean J Intern Med 2011;26:440–448.
9. Lee MH, Kim HC, Ahn SV, Hur NW, Choi DP, Park CG, Suh I. Prevalence of dyslipidemia among Korean adults: Korea National Health and Nutrition Survey 1998-2005. Diabetes Metab J 2012;36:43–55.
10. Park HS, Kim SM, Lee JS, Lee J, Han JH, Yoon DK, Baik SH, Choi DS, Choi KM. Prevalence and trends of metabolic syndrome in Korea: Korean National Health and Nutrition Survey 1998-2001. Diabetes Obes Metab 2007;9:50–58.
11. He J, Gu D, Reynolds K, Wu X, Muntner P, Zhao J, Chen J, Liu D, Mo J, Whelton PK. InterASIA Collaborative Group. Serum total and lipoprotein cholesterol levels and awareness, treatment, and control of hypercholesterolemia in China. Circulation 2004;110:405–411.